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Background: Although vascular endothelial growth factor (VEGF) is elevated in patients with acute
myocardial infarction (AMI), the clinical signiﬁcance of its elevation remains unclear. The present study
was designed to determine the relationship between VEGF and left ventricular dimension in patients
with AMI.
Methods and results: Plasma VEGF levels were examined by enzyme-linked immunosorbent assay daily
for one week and then weekly for four weeks in 38 patients with AMI (65.4±1.7 years). Left ventricu-
lography was performed at 14 days, 6 months, and 2 years after the onset of AMI. Plasma VEGF levels
were signiﬁcantly elevated and reached a peak on day 6. Peak plasma VEGF levels positively correlated
with both end-diastolic and end-systolic volume indices at 14 days after the onset of AMI. When patients
with AMI were divided into two groups according to plasma VEGF levels on admission, left ventricular
volume indices were higher in the high VEGF group than in the low VEGF group at the subacute phase of
AMI (14 days). These differences were no longer present in the chronic phase of AMI.
Conclusion: Plasma VEGF levels were increased in patients with AMI, and peak levels were associated
with left ventricular volume indices in the subacute phase, suggesting an important role of endogenous
VEGF in the left ventricular dimension in patients with AMI.
4 Jap© 201
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Vascular endothelial growth factor (VEGF) [1] is an impor-
ant endothelial cell-speciﬁc mitogen. VEGF enhances vascular
ermeability [2,3], accelerates collateral formation in ischemic
yocardium [4–6], and promotes tissue repair after wound heal-
ng [7]. Several reports have demonstrated that patients with acute
yocardial infarction (AMI) have elevated circulating VEGF levels
s compared with healthy subjects [8–12]. Treatment with exoge-
ous VEGF promoted vessel formation in ischemic myocardium
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and improved ventricular function in patients with ischemic heart
diseases [13,14]. On the other hand, granulocyte colony stimulat-
ing factor upregulated VEGF and improved survival by accelerating
neovascularization in a rabbit model of myocardial ischemia [15].
However, the clinical signiﬁcance of endogenous VEGF in patients
with AMI has not been fully understood.
The relationship between plasma VEGF levels and subsequent
cardiac dimension in patients with AMI is controversial. Soeki et al.
deﬁned the remodeling group as having an increase in left ventri-
cular end-diastolic volume index (LVEDVI) more than 5ml/m2 at 3
months after the onset of AMI. They found no changes in VEGF lev-
els between the remodeling group and the non-remodeling group
[11]. On the other hand, Suzuki et al. deﬁned the remodeling group
as showing an increase in LVEDVI at one month after the onset of
AMI and demonstrated that peak VEGF levels were signiﬁcantly
higher in the remodeling group than in the non-remodeling group
served.
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12]. However, there are no reports investigating the relationship
etweenpeakVEGF levels and left ventricular volume indices at the
ore chronic phase of AMI, such as 6 months or 2 years after the
nset of AMI. Therefore, the aim of the present study was to exam-
ne the time course of plasma VEGF levels in patientswith AMI, and
o investigate the correlation between plasma VEGF levels and left
entricular dimension in the early and chronic phase of AMI.
ethods
atient characteristics
The present study included 38 patients (27 males and 11
emales, mean age 65.4±1.7 years) with AMI who were admitted
o the National Hospital Organization Kagoshima Medical Center
ithin 12hours after the onset of symptoms and had successful
eperfusion therapy with percutaneous coronary intervention
rom August 2001 to July 2002. The clinical characteristics and
edication in all patients with AMI are shown in Tables 1 and 2,
espectively. The diagnosis of AMI was based on the ﬁndings
f severe prolonged chest pain for at least 30min, ST-segment
levation of at least two continuous leads by a standard 12-lead
lectrocardiogram, and elevation of serum creatine kinase (CK)-
B isozyme to more than twice the upper limit of normal range.
atients with AMI more than 12h from the onset and those with
MI who had already received heparin treatment before admis-
ion to our hospital were excluded in the present study. Patients
ith preexisting heart diseases including previous myocardial
nfarction, valvular heart disease, and cardiomyopathy were also
xcluded. Other exclusion criteriawere renal dysfunction requiring
ialysis and evidence of malignant and inﬂammatory diseases. All
atientsweremonitored in our intensive care unit and entered into
he cardiac rehabilitation programs in our hospital. Age-matched
2 subjects (13 men and 9 women, mean age 63.7±1.5 years)
aving atypical chest pain with angiographically normal coronary
rteries and a normal left ventriculogram served as control sub-
ects. The investigation conforms to the principles outlined in the
able 1
atient characteristics in high VEGF group and low VEGF group.
Total H
(n=38) (
Age (years) 65.4±1.7
Sex (%)
Male 27 (71.0)
Female 11 (29.0)
BMI (kg/m2) 24.4±0.5
Risk factors
Hypertension (%) 24 (63.2)
Hyperlipidemia (%) 17 (44.7)
Diabetes mellitus (%) 16 (42.1)
Smoking (%) 12 (31.6)
Killip classiﬁcation
I 30 (78.9)
II 8 (21.1)
Time to reperfusion (h) 3.9±0.4
Diseased vessels
Single-vessel disease 24 (63.2)
Multivessel disease 14 (36.8)
Rentrop collateral grade
0/1 23 (60.5)
2/3 15 (39.5)
CI (L/min/m2) 3.59±0.2
PCWP (mmHg) 13.7±1.1
LVEF (UCG) (%) 58.2±1.9
Peak CK (IU/L) 3029±320 3
Peak BNP (pg/ml) 240±31
alues are expressed as number (percentage) of patients or mean value± SE. VEGF, vascu
ndex; PCWP, pulmonary capillarywedge pressure; LVEF, left ventricular ejection fraction;ardiology 64 (2014) 360–365 361
Declaration of Helsinki, and it was approved by the Institutional
Review Board in our hospital. Written informed consent was
obtained from each patient with AMI and also from the control
subjects.
Blood sampling
Peripheral blood samples were obtained immediately before
administration of heparin at the time of admission, daily for one
week, and then weekly for four weeks in patients with AMI. B-type
natriuretic peptide (BNP) was also examined.
Measurement of VEGF levels
Plasma samples for the measurement of VEGF were placed
in ethylenediaminetetraacetic acid-coated tubes containing
500 IU/ml of aprotinine, centrifuged immediately at 3000 rpm
for 10min at 4 ◦C, and stored at −80 ◦C until analysis. Plasma
VEGF levels were determined using a speciﬁc enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s instructions. The minimal
detection limit of this ELISA was 31.2pg/ml. VEGF levels were
deﬁned as zero if the values were less than the minimal detection
limit. VEGF assay was performed by an investigator blinded to the
sources of the samples. Intra-assay and inter-assay variations were
5.6% and 9.8%, respectively.
Ultrasound cardiography
Standard two-dimensional and Doppler echocardiographic
examinations were performed at admission, at 28 days, 6 months,
and 2 years after the onset of AMI. Left ventricular end-diastolic
diameter (LVDd) and left ventricular end-systolic diameter (LVDs)
were measured by two-dimensional and M-mode echocardiog-
raphy. Ejection fraction (EF, Simpson method) was calculated
according to the standard formula.
igh Low p-Value
n=12) (n=26)
69.8±3.5 63.3±1.8 NS
10 (83.3) 17 (65.4) NS
2 (16.7) 9 (34.6) NS
25.3±1.0 24.0±0.5 NS
5 (41.7) 9 (34.6) NS
4 (33.3) 13 (50) NS
4 (33.3) 12 (46.2) NS
6 (50.0) 6 (23.1) NS
8 (66.7) 22 (84.6) NS
4 (33.3) 4 (15.3) NS
3.3±0.4 4.1±0.6 NS
5 (41.7) 19 (73.1) NS
7 (58.3) 7 (26.9) NS
6 (50.0) 17 (65.4) NS
6 (50.0) 9 (34.6) NS
3.2±0.19 3.8±0.2 NS
15.9±2.8 12.8±1.1 NS
52.7±3.7 60.9±1.9 NS
614±661 2759±352 NS
260±75 229±37 NS
lar endothelial growth factor; NS, not signiﬁcant; BMI, body mass index; CI, cardiac
UCG, ultrasound cardiography; CK, creatine kinase; BNP, B-type natriuretic peptide.
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Table 2
Medication on admission, at discharge, at 6 months and 2 years after the onset of AMI in high VEGF group and low VEGF group.
On admission (%) Discharge (%) 6 months (%) 2 years (%)
High Low p-Value High Low p-Value High Low p-Value High Low p-Value
(n=12) (n=26) (n=12) (n=26) (n=6) (n=21) (n=4) (n=7)
ACE inhibitor 1 (8.3) 1 (3.8) NS 6 (50.0) 11 (42.3) NS 2 (33.3) 7 (33.3) NS 2 (50) 2 (28.6) NS
Angiotensin receptor blocker 0 (0) 3 (11.5) NS 5 (41.7) 13 (50.0) NS 4 (66.6) 12 (57.1) NS 2 (50) 4 (57.1) NS
Calcium-channel blocker 4 (33.3) 7 (26.9) NS 4 (33.3) 7 (26.9) NS 1 (16.7) 6 (28.5) NS 1 (25) 4 (57.1) NS
Spironolactone 0 (0) 0 (0) NS 2 (16.7) 5 (19.2) NS 1 (16.7) 4 (19.0) NS 1 (25) 0 (0) NS
Statin 0 (0) 2 (7.7) NS 3 (25.0) 9 (34.6) NS 3 (50.0) 7 (33.3) NS 2 (50) 3 (42.9) NS
V farction; VEGF, vascular endothelial growth factor; ACE, angiotensin converting enzyme;
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Fig. 1. Time course of plasma vascular endothelial growth factor (VEGF) levels inalues are expressed as number (percentage) of patients. AMI, acute myocardial in
S, not signiﬁcant.
ardiac catheterization
All patients with AMI were transferred to the catheterization
aboratory, and underwent percutaneous coronary intervention
PCI) immediately after admission (n=38). Right-sided cardiac
atheterization was performed for the measurement of pulmonary
apillary wedge pressure (PCWP) and cardiac index (CI) just before
CI. No patients had a culprit lesion at the left main trunk, and
ost-PCI restenosis was not observed in any patients with AMI.
ime to reperfusion, diseased vessels, and Rentrop collateral grad-
ng are shown in Table 1. Left ventriculography was performed
or the measurement of LVEDVI and left ventricular end-systolic
olume index (LVESVI) using computer-assisted analysis system
QCA-CMS; Goodman Co., Ltd., Nagoya, Japan). For the follow-
p study, cardiac catheterization was also performed at 14 days
n=27), 6 months (n=27), and 2 years (n=11) after the onset of
MI.
tatistical analysis
All data are shown as means± SE. Statistical analysis was per-
ormed using StatView J-5.0 (SAS Institute Inc., Cary, NC, USA).
ategorical variables were compared by chi-square analysis with
isher’s exact probability. The plasma levels of VEGF over the time
ourse of AMI were analyzed using analysis of variance (ANOVA)
or repeated measures. Comparison of parameters between two
roups was performed with the unpaired Student’s t-test. The rela-
ionship between VEGF levels and left ventricular volume indices
r other parameters was examined by linear regression analysis.
alues of p<0.05 were considered statistically signiﬁcant.
esults
lasma VEGF levels in patients with AMI
Fig. 1 shows the time course of plasma VEGF levels for 4
eeks in patients with AMI. Plasma VEGF levels from day 5 to
ay 7 were signiﬁcantly higher in patients with AMI than those
27.9±14.4pg/ml) in control subjects. Plasma VEGF levels reached
peak on day 6 (104.5±27.2pg/ml), and gradually decreased
hereafter. We then investigated the relationship between the
eak plasma VEGF levels and the clinical parameters in patients
ith AMI. Peak plasma VEGF levels showed no correlations with
chocardiographic or hemodynamic parameters on admission. In
ddition, peak plasma VEGF levels had no correlations with age,
ender, risk factors, or peak CK levels in patients with AMI. In
8 patients with AMI, 27 patients received cardiac catheterization
t 14 days after the onset of AMI, and LVEDVI as well as LVESVI
ere calculated by area-length methods as described above. As
hown in Fig. 2, peak plasma VEGF levels positively correlated
ith LVEDVI (r=0.51, p=0.0057) and LVESVI (r=0.57, p=0.0016)
n these 27 patients with AMI. We further performed follow-uppatientswith acutemyocardial infarction. PlasmaVEGF levels reached a peak onday
6, and gradually decreased thereafter. Values are mean± SEM. *p<0.05 compared
with values on admission. †p<0.05 compared with values in the control subjects.
cardiac catheterization at 6 months (n=27) and 2 years (n=11)
after the onset of AMI, and examined LVEDVI and LVESVI in these
patients. However, the correlations seen at 14 days and 6 months
after the onset of AMI disappeared at 6 months and 2 years after
the onset of AMI.
Therefore,we investigated the correlationbetweenpeakplasma
VEGF levels and changes in LVEDVI and LVESVI from 14 days to
6 months and from 14 days to 2 years after the onset of AMI. As
shown in Fig. 3, peak plasma VEGF levels had inverse correlations
with changes in LVEDVI and LVESVI from 14 days to 6 months
after the onset of AMI (Fig. 3A and B). Although the number of AMI
patients was less, similar correlations were observed between the
peak plasma VEGF levels and changes in LVEDVI and LVESVI from
14 days to 2 years (Fig. 3C and D).
High VEGF group and low VEGF group
In 38 patients with AMI, 26 patients had plasma VEGF levels
less than the minimal detection limit of VEGF assay on admission.
Therefore, we investigated whether clinical parameters including
echocardiographic andhemodynamicparameters aswell asplasma
VEGF levels in these 26 AMI patients (low VEGF group) were differ-
ent from those in the remaining 12AMI patients (highVEGF group).
Fig. 4 illustrates the time course of plasma VEGF levels in these two
groups. In the high VEGF group, the plasma VEGF levels remained
elevated until 21 days after the onset of AMI as compared with the
lowVEGFgroup. Thedifferences in plasmaVEGF levels between the
two groups disappeared on day 28. The clinical characteristics and
the medication in the high VEGF group and the low VEGF group
are shown in Tables 1 and 2, respectively. There were no signif-
icant differences between the two groups. In 27 AMI patients in
whom cardiac catheterization was performed at 14 days after the
onset of AMI, 6 patients belonged to the high VEGF group and 21
H. Shimokawahara et al. / Journal of Cardiology 64 (2014) 360–365 363
Fig. 2. Correlations between peak plasmaVEGF levels and LVEDVI (left) and between peak plasmaVEGF levels and LVESVI (right) at 14 days after the onset of acutemyocardial
infarction. Signiﬁcant positive correlations were observed between peak plasma VEGF levels and LVEDVI (r=0.51, p=0.0057) and between peak plasma VEGF levels and
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atients belonged to the low VEGF group. In these 27 AMI patients,
oth LVEDVI and LVESVI were signiﬁcantly higher in the high VEGF
roup than in the low VEGF group (Fig. 5). We also investigated the
hanges in LVEDVI and LVESVI from 14 days to 6 months after the
nset of AMI. Both LVEDVI and LVESVI in the high VEGF group sig-
iﬁcantly decreased, and those in the low VEGF group signiﬁcantly
ncreased at 6 months after the onset of AMI. The differences in
VEDVI and LVESVI between the two groups observed at 14 days
isappeared at 6 months after the onset of AMI. There were no sig-
iﬁcant differences in LVEDVI and LVEDVI between the two groups
t 2 years after the onset of AMI as well (data not shown).
ig. 3. Correlations between peak plasma VEGF levels and changes in LVEDVI and LVES
yocardial infarction. Peak plasma VEGF levels had inverse correlations with changes i
ears, r=−0.80, p=0.002) and with LVESVI (B, from 14 days to 6 months, r=−0.67, p<0.00
LVESVI, changes in LVESVI. VEGF, vascular endothelial growth factor; LVEDVI, left ven
ndex.ular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index.
Discussion
The present study demonstrated that plasma VEGF levels were
signiﬁcantly elevated from day 5 to day 7 in patients with AMI
compared with the levels in the control subjects. These ﬁndings
were supported by previous studies that patients with AMI have
elevated circulating VEGF levels compared with control subjects
[8–12]. Precise mechanisms of plasma VEGF elevation in patients
with AMI are not fully understood. Hypoxia is a strong inducer
of VEGF expression in the heart [16]. Inﬂammation is another
important factor activating plasma VEGF levels in patients with
VI from 14 days to 6 months and from 14 days to 2 years after the onset of acute
n LVEDVI (A, from 14 days to 6 months, r=−0.46, p=0.015; C, from 14 days to 2
01; D, from 14 days to 2 years, r=−0.86, p=0.0003). LVEDVI, changes in LVEDVI;
tricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume
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MI [17,18]. Speciﬁcally, Sasaki et al. previously demonstrated that
eripheral bloodmononuclear cell, an independent predictor of left
entricular remodeling after AMI [19], is considered the source for
irculating VEGF in patients with AMI [20]. Alternatively, ventricu-
ar stretch or expansion may also augment VEGF expression in the
eart, leading to an increase in plasma VEGF levels in patients with
MI. Li et al. reported that mechanical stretch in the left ventricle
nduced an increase in VEGF gene expression [21]. In the present
tudy, the peak plasma VEGF levels positively correlated with left
entricular volume indices in the subacute phase of AMI. Therefore,
EGF may be released from the heart in relation to left ventricular
tretch after AMI. As for the possible molecular mechanisms, the
revious investigations demonstrated that stretch-induced VEGF
pregulation is mediated at least in part by tumor growth factor
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ig. 5. LVEDVI and LVESVI in the high VEGF group and in the low VEGF group at 14 days
igher in the high VEGF group (black bar) than in the low VEGF group (gray bar) at 14 da
ecreased, and those in the low VEGF group signiﬁcantly increased at 6 months after th
ith 14 days after the onset of AMI in each group. LVEDVI, left ventricular end-diastolic
ndothelial growth factor; AMI, acute myocardial infarction.Cardiology 64 (2014) 360–365
(TGF)- [21,22], hypoxia inducible factor (HIF)1 [23], and nuclear
factor B (NFB) [24].
Previous investigators showed a signiﬁcant positive correlation
between peak VEGF levels and LVEDVI at fourweeks after the onset
of AMI [12]. However, there have been no reports demonstrating
the relationship between peak VEGF levels and left ventricular vol-
ume indices at the chronic phase of AMI. In the present study, we
demonstrated that peak plasma VEGF levels correlated not only
with LVEDVI but also with LVESVI at the subacute phase of AMI (14
days after the onset of AMI). Moreover, peak plasma VEGF levels
showed inverse correlations with changes in LVEDVI and LVESVI
from 14 days to 6 months as well as from 14 days to 2 years after
the onset of AMI. The differences in LVEDVI and LVESVI between
the high and low VEGF groups observed at the subacute phase of
AMI disappeared at the chronic phase of AMI. These ﬁndings indi-
cated that the higher the peak plasma VEGF levels reached, the
larger the left ventricular volume progressed at the subacute phase
of AMI. In addition, thehigher thepeakplasmaVEGF levels reached,
the smaller the left ventricular volume size changed at the chronic
phase of AMI. In experimental animal models of AMI, VEGF protein
injectionorVEGFgene transfer reduced scar size in the left ventricle
[25,26]. Although the present study did not investigate the causal
relationship between VEGF and ventricular remodeling [27], the
elevation of endogenous VEGF after the onset of AMI is considered
beneﬁcial with regard to left ventricular remodeling via infarct size
reduction.
Study limitations
There are several limitations to this study. This was a retrospec-
tive observational study and the number of patients was relatively
small. As we have not performed left ventriculography on admis-
sion, we could not evaluate changes in left ventricular volume
indices from acute to subacute or from acute to chronic phase
: High VEGF group
: Low VEGF group
6 months
6 months
and 6 months after the onset of AMI. LVEDVI (A) and LVESVI (B) were signiﬁcantly
ys after the onset of AMI. LVEDVI and LVESVI in the high VEGF group signiﬁcantly
e onset of AMI. *p<0.05 compared with the low VEGF group. †p<0.05 compared
volume index; LVESVI, left ventricular end-systolic volume index; VEGF, vascular
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f AMI. On the other hand, we do not have results of long-term
ollow-up data >2 years. In addition, we did not investigate the
resence of concomitant ischemic diseases such as cerebrovascu-
ar disease and peripheral arterial disease in these patients with
MI. A randomized controlled study based on a greater number
f patients with a longer observational period is needed to con-
rm our results. Another limitation was the inﬂuence of heparin
n measuring the plasma VEGF levels, because heparin is known
o reduce plasma VEGF levels [8,28], and heparin is routinely used
uring the treatment of AMI for a few days. In the present study,
atients with AMI who had already received heparin treatment
efore admission to our hospital were excluded, so that the plasma
EGF levels on admission were without the inﬂuence of heparin.
e used 100 IU/kg intravenous bolus injection of heparin at the
ime of emergency cardiac catheterization, followed by continuous
nfusion at the dose of 0.1 IU/kg/min for three days. Therefore, the
lasma samples fromday1 to day 3were obtainedunder treatment
ith heparin, and there is a possibility that plasma VEGF levels
ithin the ﬁrst three daysmight be underestimated.We conﬁrmed
hat ELISA itself for measuring VEGF was substantially unaffected
y the administration of heparin.
onclusions
In conclusion, the present study has demonstrated that plasma
EGF levels are increased in patients with AMI as compared with
he control subjects, and that peak plasma VEGF levels correlated
ositively with left ventricular volume indices at the subacute
hase of AMI. This study provides a new insight into the signif-
cance of VEGF in association with left ventricular dimension in
atients with AMI.
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